Floatz logo

Trastuzumab Deruxtecan

Brain Metastases

Baptist Health South Floridaantibody_drug_conjugatePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

102 Active assets in the Brain Metastases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Copper Cu 64-DOTA-Trastuzumab
City of Hope Medical Center
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →